Enfortumab Vedotin Combo Data in Urothelial Carcinoma Are ‘Compelling’
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.